prednisone has been researched along with lenalidomide in 159 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (10.06) | 29.6817 |
| 2010's | 106 (66.67) | 24.3611 |
| 2020's | 37 (23.27) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Silver, R | 1 |
| Kyle, RA; Vincent Rajkumar, S | 1 |
| Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB | 1 |
| Fassas, AB; Tricot, G | 1 |
| Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Ganser, A; Peest, D | 1 |
| Faiman, B | 1 |
| Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV | 1 |
| Facon, T; Hulin, C; Moreau, P | 2 |
| Bladé, J; Rosiñol, L | 1 |
| Ambrus, JL; Islam, A | 1 |
| Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC | 1 |
| Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S | 1 |
| Azaïs, I; Brault, R; Debiais, F | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F | 1 |
| Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G | 1 |
| Boccadoro, M; Dispenzieri, A; Falco, P; Gay, F; Gertz, MA; Keith Stewart, A; Kumar, S; Palumbo, A; Petrucci, MT; Vincent Rajkumar, S | 1 |
| Lonial, S | 1 |
| Cripe, LD; Li, CY; Litzow, M; Mesa, RA; Paietta, E; Rowe, JM; Tallman, MS; Tefferi, A; Yao, X | 1 |
| de Witte, T; Holle, N; Mandigers, C; Raymakers, R; Schaap, N | 1 |
| Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Mateos, MV; San-Miguel, J | 1 |
| Schots, R | 1 |
| Kyle, RA; Steensma, DP | 1 |
| Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M | 1 |
| Rexer, H | 1 |
| Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE | 1 |
| Abkowitz, JL; Keel, SB; Kirn-Safran, CB; O'Leary, MN; Phelps, S; Sabo, KM | 1 |
| Abumiya, M; Kameoka, Y; Miura, M; Sawada, K; Takahashi, N | 1 |
| Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL | 1 |
| Habermann, TM | 1 |
| Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M | 1 |
| Badros, AZ | 1 |
| Charliński, G; Jedrzejczak, WW; Wiater, E | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D | 1 |
| Harousseau, JL | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Carella, AM; Cavallo, F; De Paoli, L; Falco, P; Freilone, R; Gaidano, G; Gay, F; Grasso, M; Guglielmelli, T; Larocca, A; Mina, R; Molica, S; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Rocci, A; Rossi, D; Siez, ML | 1 |
| Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ | 1 |
| Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L | 1 |
| Beckers, MM; Huls, G | 1 |
| Rajkumar, SV | 1 |
| Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J | 1 |
| Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST | 1 |
| Lonial, S; Miguel, JF | 1 |
| Mina, R; Palumbo, A | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M | 1 |
| Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J | 1 |
| Amías-Lamana, V; Cabiró-Badimón, I; Hoyos-Chacón, J; Mesa-Gutiérrez, JC; Porta-Monnet, J; Rouras-López, A | 1 |
| Agostinelli, C; Argnani, L; Broccoli, A; Celli, M; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Delforge, M; Devos, T; Dierickx, D; Janssens, A; Raddoux, J; Verhoef, G; Zelis, N | 1 |
| Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT | 1 |
| Baldi, I; Botto, B; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; Congiu, A; Dreyling, M; Fattori, PP; Franceschetti, S; Gaidano, G; Gaudiano, M; Inghirami, G; Ladetto, M; Liberati, AM; Molinari, AL; Pavone, V; Rossi, G; Salvi, F; Spina, M; Vitolo, U; Zaccaria, A; Zanni, M; Zinzani, P | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A | 1 |
| Ansell, SM; Foran, JM; Gascoyne, RD; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; Macon, WR; Micallef, IN; Nelson, GD; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Thompson, CA; Witzig, TE | 1 |
| Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S | 1 |
| Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E | 1 |
| Anderson, K; Attal, M; Avet-Loiseau, H; Bahlis, N; Banos, A; Belch, AR; Benboubker, L; Binder, D; Catalano, J; Cavenagh, J; Cavo, M; Chen, C; Chen, G; de la Rubia, J; Delforge, M; Dimopoulos, MA; Dispenzieri, A; Ervin-Haynes, A; Facon, T; Fermand, JP; Geraldes, C; Hulin, C; Jacques, C; Knight, R; Lee, JJ; Ludwig, H; Moreau, P; Oriol, A; Pinto, A; Qiu, L; Tiab, M; Van Oostendorp, J; Weisel, K; White, DJ | 1 |
| Yamamoto, K | 1 |
| Tsurumi, H | 1 |
| Escudero-Vilaplana, V; Osorio Prendes, S; Sanjurjo Sáez, M | 1 |
| Fowler, NH | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Olza, MO; de Wit, R; Doner, K; Fandi, A; Fizazi, K; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, S; Petrylak, DP; Sternberg, CN; Van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Arnulf, B; Bahlis, NJ; Canepa, L; Delforge, M; Eisenmann, JC; Ervin-Haynes, A; Escoffre-Barbe, M; Ezaydi, Y; Facon, T; Fragasso, A; Giraldo-Castellano, P; Guo, S; Houck, V; Langer, C; Lemieux, B; Leyvraz, S; Minuk, L; Monzini, MS; Song, K; Vogl, DT; Yoon, SS; Zarnitsky, C | 1 |
| Allred, J; Bergsagel, PL; Buadi, FK; Dispenzieri, A; Fonseca, R; Gertz, MA; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Rajkumar, SV; Reeder, CB; Rivera, CE; Roy, V; Stewart, AK | 1 |
| Cejalvo, MJ; de la Rubia, J | 1 |
| McCormack, PL | 1 |
| Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S | 1 |
| Benevolo, G; Boccadifuoco, L; Boccadoro, M; Caravita, T; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Donato, F; Gay, F; Guglielmelli, T; Hajek, R; Hardan, I; Jacques, C; Larocca, A; Musto, P; Nagler, A; Nozzoli, C; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Vincelli, D; Yu, Z | 1 |
| Kusec, R; Livun, A; Manshouri, T; Newberry, KJ; Verstovsek, S | 1 |
| Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI | 1 |
| Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W | 1 |
| Holstein, SA; McCarthy, PL | 1 |
| Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A | 1 |
| Facon, T | 1 |
| Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R | 1 |
| Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB | 1 |
| Adesunloye, BA; Arlen, PM; Beedie, SL; Chen, C; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Harold, N; Huang, X; Karzai, FH; Lee, MJ; Lee, S; Madan, RA; McLeod, DG; Ning, YM; Rosner, I; Sissung, T; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB | 1 |
| Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S | 1 |
| Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A | 1 |
| Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
| Chiappella, A; Flament, J; Gascoyne, RD; Nowakowski, GS; Repici, J; Spina, M; Vitolo, U; Witzig, TE; Zhang, L | 1 |
| Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB | 1 |
| Azais, I; Belch, A; Chen, G; Dakhil, S; Dimopoulos, MA; Doyen, C; Dührsen, U; Eek, R; Ervin-Haynes, A; Facon, T; Garderet, L; Gisslinger, H; Goncalves, C; Houck, V; Hulin, C; Hunter, H; LeBlanc, R; Leleu, X; Leupin, N; Lu, J; Macro, M; Offner, F; Pégourié, B; Petrucci, MT; Rodon, P; Romeril, K; Royer, B; Shustik, C; Song, K | 1 |
| Chihara, D; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, H; Maeng, H; Masarova, L; Newberry, KJ; Ravandi, F; Verstovsek, S | 1 |
| Chan, TS; Khong, PL; Kwong, YL | 1 |
| Barton, D; Bellmunt, J; Berry, WR; Burke, JM; Crane, E; De Wit, R; Doner, K; Fandi, A; Fizazi, K; Gandhi, A; Hainsworth, JD; Hutson, TE; Jungnelius, U; Liu, K; Petrylak, DP; Sternberg, CN; Vogelzang, NJ; Waldman, MF; Wiechno, PJ | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Morrée, ES; de Wit, R; Doner, K; Fandi, A; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, JS; Li, S; Ochoa de Olza, M; Petrylak, DP; Sternberg, CN; van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S | 1 |
| Bringhen, S; Di Raimondo, F; Gay, F; Gentile, M; Grazia Recchia, A; Greco, R; Larocca, A; Magarotto, V; Morabito, F; Musto, P; Offidani, M; Palumbo, A; Petrungaro, A; Ria, R; Teresa Petrucci, M; Tripepi, G; Uccello, G; Vigna, E | 1 |
| Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS | 1 |
| Ko, C; Leventhal, J; Much, M; Stahl, M; Weed, J; Witt, D; Zeidan, AM | 1 |
| Bahlis, NJ; Basu, S; Chen, G; Corso, A; de Revel, T; Decaux, O; Demuynck, H; Desjardins, P; Ervin-Haynes, A; Facon, T; Granell, M; Guthrie, TH; Huang, SY; Marek, J; Marit, G; Mugge, LO; Nahi, H; Shen, ZX; Stoppa, AM | 1 |
| Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A | 1 |
| Witzig, TE | 1 |
| Altenbuchinger, M; Bertoni, F; Cascione, L; Chiappella, A; Ciccone, G; Inghirami, G; Kohler, C; Kwee, I; Rinaldi, A; Vitolo, U | 1 |
| Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL | 1 |
| Bourquard, P; Chevallier, T; Cousin, C; Dubois, F; Favier, M; Favier-Archinard, C; Le Gall, T; Leguelinel-Blache, G; Passemard, N; Rey, A; Rossi, M; Tora, S | 1 |
| Belickova, M; Cmunt, E; Fuchs, O; Jonasova, A; Michalova, K; Minarik, L; Moudra, A; Neuwirtova, R; Polackova, H; Siskova, M; Stopka, T; Zemanova, Z | 1 |
| Ayed, AO; Cavallo, F; Chiappella, A; Congiu, AG; Gaidano, G; Laplant, BR; Macon, WR; Musuraca, G; Nowakowski, GS; Pederson, L; Re, A; Spina, M; Vitolo, U; Witzig, T | 1 |
| Till, BG | 1 |
| Gilbert, L; Ordway, S; Wanko, S | 1 |
| Gordon, LI | 1 |
| Becker, S; Bouabdallah, R; Cabeçadas, J; Casasnovas, O; Feugier, P; Gabarre, J; Gouill, SL; Haioun, C; Jardin, F; Lamy, T; Molina, TJ; Morschhauser, F; Mounier, N; Salles, G; Tilly, H; Tournilhac, O | 1 |
| Anwer, F; Durer, C; Durer, S; Faridi, W; Fraz, MA; Ijaz, A; Khan, AY; Kumar, A; Malik, SU; Nasar, A; Qureshi, A; Tariq, MJ; Usman, M | 1 |
| Ansell, SM; Castellino, A; Cavallo, F; Chiappella, A; Ciccone, G; Congiu, A; Foran, JM; Gaidano, G; Habermann, TM; Inghirami, G; King, RL; LaPlant, BR; Macon, WR; Molinari, AL; Nowakowski, GS; Pavone, V; Pederson, LD; Reeder, CB; Rivera, CE; Spina, M; Tucci, A; Vitolo, U; Witzig, TE | 1 |
| Bai, H; Chen, JW; Fan, WJ; Wu, T | 1 |
| Bashir, Q; Champlin, RE; Delgado, R; Hosing, C; Kebriaei, P; Lee, HC; Manasanch, EE; Nieto, Y; Orlowski, RZ; Patel, KK; Patel, RD; Popat, U; Qazilbash, MH; Rondon, G; Saini, NY; Thomas, SK; Varma, A; Weber, DM | 1 |
| Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S | 1 |
| Chukavina, MM; Gabeeva, NG; Koroleva, DA; Kovrigina, AM; Obukhova, TN; Zvonkov, EE | 1 |
| Bishop, MR; Cohen, KS; Godfrey, JK; Karmali, R; Karrison, T; Kline, JP; Nabhan, C; Rapoport, AP; Smith, SM; Stadler, WM; Venugopal, P | 1 |
| Al Ali, NH; Cogle, C; Komrokji, RS; Lancet, JE; Lis, AF; Padron, E; Sallman, D; Tinsley, S | 1 |
| Amico, V; Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Cangiolosi, C; De Paoli, L; Evangelista, A; Falcone, AP; Fraticelli, V; Giuliani, N; Hájek, R; Innao, V; Larocca, A; Ledda, A; Liberati, AM; Mina, R; Montefusco, V; Musto, P; Oddolo, D; Offidani, M; Palumbo, A; Paris, L; Patriarca, F; Romano, A; Spada, S; Zambello, R | 1 |
| Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E | 1 |
| Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S | 1 |
| Aquino, S; Baldini, L; Ballanti, S; Boccadoro, M; Bringhen, S; Cellini, C; D'Agostino, M; De Rosa, L; Falco, P; Gazzera, G; Gentile, M; Grasso, M; Hájek, R; Larocca, A; Marasca, R; Palumbo, A; Paris, L; Pavone, V; Pescosta, N; Petrucci, MT; Pezzatti, S; Poggiu, M; Rota-Scalabrini, D; Santoro, A; Spada, S; Tosi, P | 1 |
| Cavo, M; Dimopoulos, MA; Facon, T; Gebregergish, SB; Heeg, B; Lam, A; Mateos, MV; Nair, S; Pisini, M; Slavcev, M; van Beekhuizen, S | 1 |
| Abraham, J; Bouabdallah, R; Bron, D; Caballero, D; Casadebaig, ML; Casasnovas, RO; Catalano, J; Cohen, AM; Coiffier, B; Costello, R; da Silva, MG; Daguindau, N; Deeren, D; Eisenmann, JC; Fitoussi, O; Fruchart, C; Gaulard, P; Gonzalez, H; Greil, R; Grosicki, S; Howlett, S; Le Du, K; Lionne-Huyghe, P; Morschhauser, F; Mounier, N; Nicolas-Virezelier, E; Obéric, L; Perrot, A; Pica, GM; Roulin, L; Snauwaert, S; Takeshita, K; Thieblemont, C; Tilly, H; Tricot, S; Trotman, J; van Eygen, K | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Abraham, J; Bouabdallah, R; Briere, J; Casasnovas, O; Chartier, L; Choufi, B; Corront, B; Cottereau, AS; Feugier, P; Fitoussi, O; Fruchart, C; Gaulard, P; Godmer, P; Gonzalez, H; López-Guillermo, A; Meignan, M; Morschhauser, F; Oberic, L; Pica, GM; Ribrag, V; Roulin, L; Salles, G; Sanhes, L; Sebban, C; Simon, M; Snauwaert, S; Thieblemont, C; Tilly, H; Trotman, J; Vercellino, L | 1 |
| Ansell, SM; Asmann, Y; Cerhan, JR; Feldman, AL; Gandhi, AK; Habermann, TM; Hartert, KT; King, RL; Krull, JE; Larson, MC; Link, BK; Macon, WR; Manske, M; Maurer, MJ; Novak, AJ; Nowakowski, GS; Sarangi, V; Slager, S; Wenzl, K; Witzig, TE; Yang, ZZ | 1 |
| Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D | 1 |
| Lue, JK; O'Connor, OA | 1 |
| Abonour, R; Agarwal, A; Ailawadhi, S; Durie, BGM; Gasparetto, C; Hardin, JW; Jagannath, S; Kitali, A; Lee, HC; Narang, M; Omel, JL; Rifkin, RM; Srinivasan, S; Terebelo, HR; Toomey, K; Wagner, L | 1 |
| Chen, M; Chen, W; Jiang, Q; Li, T; Liu, Y; Peng, J; Shi, X; Wu, J; Xi, X; Yu, X; Zhang, S; Zhu, Y | 1 |
| Carson, R; Chari, A; Delioukina, M; Hulin, C; Hungria, V; Iida, S; Karlin, L; Kosh, M; Magen, H; Maisnar, V; Masterson, T; McCarthy, H; Parasrampuria, DA; Perrot, A; Pour, L; Qi, M; Rodriguez-Otero, P; Sureda Balari, A; Suzuki, K; Touzeau, C; Yang, S | 1 |
| Arens, AIJ; Bakunina, K; Beeker, A; Bilgin, YM; Boersma, RS; Bohmer, LH; Burggraaff, CN; Chamuleau, MED; de Jong, D; de Jongh, E; Diepstra, A; Dierickx, D; Durian, MF; Hijmering, N; Hoekstra, O; Huijbregts, J; Kersten, MJ; Koene, HR; Lugtenburg, PJ; Mandigers, C; Marijt, EAF; Mous, R; Nijland, M; Schouten, HC; Snijders, TJF; Tick, LW; van den Berg, A; van Imhoff, GW; van Rees, B; Vermaat, JSP; Visser, O; Zijlstra, JM | 1 |
| Horiuchi, A; Irie, R; Miyao, N; Osamura, Y; Suyama, T; Yui, T | 1 |
| Anusim, N; Gupta, A; Howard, G; Jaiyesimi, I | 1 |
| Amengual, JE; Casulo, C; Cohen, JB; Friedberg, JW; Habermann, TM; Hong, F; Kahl, BS; Khan, N; King, RL; Kostakoglu, L; Leonard, JP; Little, RF; Macon, WR; Nagargoje, GG; Nowakowski, GS; Reynolds, CM; Richards, KL; Scott, DW; Wade, JL; Wagner-Johnston, N; Witzig, TE | 1 |
| Belada, D; Bergua, JM; Cavallo, F; Chiappella, A; Czuczman, M; Gascoyne, RD; Hersey, S; Hong, X; Hudak, K; Izutsu, K; Jin, J; Jurczak, W; Kato, K; Kilcoyne, A; Mócikova, H; Molinari, AL; Nowakowski, GS; Özcan, M; Piazza, F; Russo, J; Scott, DW; Tani, M; Vitolo, U; Wade, S; Witzig, TE; Yamamoto, K; Yoon, DH; Zhang, J; Zhang, Q; Zhu, J | 1 |
| Beaupre, D; Chhabra, S; de Vos, S; Huang, DW; Kimball, AS; Kwei, K; Neuenburg, JK; Phillips, T; Ping, J; Popplewell, L; Staudt, LM; Wilson, WH; Wright, G | 1 |
| Abella, E; Alcalá, M; Bustamante, G; Cejalvo, MJ; de la Rubia, J; Duro, R; García, A; García, R; Garzón, S; González, E; González, MS; González, Y; Jarque, I; López, R; Lostaunau, G; Martí, JM; Motlló, C; Pérez-Persona, E; Ramírez-Payer, Á; Sampol, A; Sarrà, J; Sastre, JL; Vázquez-Álvarez, J | 1 |
| Cooper, DL; Goldfinger, M | 1 |
| Iida, S; Inagaki, H; Ishida, T; Ito, A; Iwasaki, H; Kusumoto, S; Masaki, A; Murase, T; Muto, R; Nakano, N; Sakamoto, Y; Takeshita, M; Tashiro, Y; Tokunaga, M; Ueda, R; Utsunomiya, A; Yonekura, K | 1 |
| Chen, G; Chen, X; Duan, Y; Fan, J; He, B; Huang, H; Liu, W; Pan, J; Shen, H; Wu, D; Zeng, Z; Zhu, M | 1 |
| Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE | 1 |
| Despas, F; Gauthier, M; Icard, C; Mocquot, P; Nogaro, JC | 1 |
| Dong, T; Jing, F; Song, W; Wang, L; Wang, Y; Xiao, S; Xue, H | 1 |
| Cahill, KE; Smith, SM | 1 |
| Aouba, A; Audemard-Verger, A; Battistella, M; Bigot, A; Brihaye, B; Cook, AR; Deriaz, S; Diot, E; El Karoui, K; Ferreira-Maldent, N; Hankard, A; Henique, H; Ingen-Housz-Oro, S; Jobard, S; Lioger, B; Magnant, J; Maillot, F; Paule, R | 1 |
| Bao, S; Chai, G; Chen, X; Liu, C; Mao, J; Zhi, Y; Zhu, J | 1 |
| Yamaguchi, M | 1 |
| Alig, SK; Alizadeh, AA; Cherng, HJ; Craig, AFM; Davis, RE; Fayad, L; Feng, L; Flowers, CR; Green, MR; Hagemeister, F; Kurtz, DM; Lee, HJ; Macaulay, CW; McDonnell, TJ; Nastoupil, LJ; Neelapu, SS; Oki, Y; Rodriguez, MA; Turturro, F; Vega, F; Westin, JR | 1 |
| Ding, K; Jiang, X; Wang, X; Yu, L | 1 |
| Bilgin, YM; Boersma, R; Bossuyt, PM; Chamuleau, MED; de Jong, D; de Jonge, AV; de Jongh, E; Dinmohamed, AG; Kersten, MJ; Koene, H; Mous, R; Nijland, M; Rutten, EGGM; Sandberg, Y; van Werkhoven, E; Veldhuis, MS; Vermaat, JSP; Zwinderman, AH | 1 |
| André, M; Belada, D; Bergua Burgues, JM; Burke, JM; Dirnberger-Hertweck, M; Duell, J; Kopeckova, K; Mukhopadhyay, A; Nowakowski, GS; Persona, EP; Pichler, P; Staber, PB; Stevens, D; Trneny, M; Wagner, S; Waldron-Lynch, M | 1 |
| Jeon, YW; Lee, JY; Min, CK; Park, SS; Shin, SH; Yahng, SA | 1 |
| Chiappella, A; Vitolo, U | 1 |
36 review(s) available for prednisone and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2008 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide | 2010 |
Thalidomide and lenalidomide in primary myelofibrosis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Hematopoiesis; Humans; Janus Kinase 2; Lenalidomide; Prednisone; Primary Myelofibrosis; Thalidomide | 2010 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
New developments in the management of diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Vincristine; Vindesine | 2012 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome | 2012 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine | 2013 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
[Standard of care and new drugs for diffuse large B-cell lymphoma].
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Discovery; Epigenesis, Genetic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Targeted Therapy; Piperidines; Prednisolone; Prednisone; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Rituximab; Thalidomide; Vincristine; Vindesine | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Thalidomide | 2015 |
Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2015 |
Maintenance therapy for multiple myeloma in the era of novel agents.
Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematology; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Transplantation, Autologous; Vorinostat | 2017 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult | 2018 |
Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Topics: Adenine; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Female; Frail Elderly; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2018 |
[Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
Topics: Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide | 2018 |
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide; Treatment Outcome | 2019 |
Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Germinal Center; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Progression-Free Survival; Vincristine | 2018 |
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Genetic Heterogeneity; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Precision Medicine; Prednisone; Prognosis; Rituximab; Vincristine | 2020 |
Lenalidomide in DLBCL: are we past the cell of origin?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2021 |
Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Male; Neoplasm Recurrence, Local; Pharmacovigilance; Prednisone; Rituximab; Thalidomide | 2022 |
Follicular Lymphoma: a Focus on Current and Emerging Therapies
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Genetic Testing; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Prednisone; Pyridones; Rituximab; Sulfonamides; Vincristine | 2022 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide | 2022 |
[Current status and future prospects of diffuse large B-cell lymphoma treatment].
Topics: Antibodies, Bispecific; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Receptors, Chimeric Antigen; Rituximab; Vincristine | 2022 |
65 trial(s) available for prednisone and lenalidomide
| Article | Year |
|---|---|
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide | 2007 |
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Thrombocytopenia | 2009 |
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Glucocorticoids; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Neutropenia; Platelet-Derived Growth Factor; Prednisone; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Transforming Growth Factor beta; Treatment Outcome | 2009 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2010 |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Thalidomide | 2010 |
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Rituximab; Survival Rate; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Prednisone; Thalidomide | 2012 |
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Survival Rate; Thalidomide | 2013 |
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Surveys and Questionnaires; Thalidomide | 2013 |
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Doxorubicin; Female; Humans; Italy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2013 |
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Quality of Life; Thalidomide; Treatment Outcome | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Vincristine | 2014 |
Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Follicular; Male; Prednisone; Rituximab; Thalidomide; Vincristine | 2014 |
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Disease-Free Survival; Economics, Pharmaceutical; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Thalidomide | 2014 |
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Phenotype; Prednisone; Prognosis; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Thalidomide; Treatment Outcome | 2015 |
Autologous transplantation and maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2014 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Placebos; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2015 |
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Female; Health Status; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide | 2015 |
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2015 |
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Quality of Life; Thalidomide | 2015 |
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2016 |
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosphamide; Czech Republic; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Risk Factors; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2015 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide | 2016 |
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bevacizumab; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Thalidomide | 2016 |
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome; Withholding Treatment | 2016 |
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult | 2016 |
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Research Design; Rituximab; Thalidomide; Vincristine | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Dexamethasone; Drug Monitoring; Female; Humans; Immunity; Lenalidomide; Male; Melphalan; Monitoring, Physiologic; Multiple Myeloma; Neoplasm, Residual; Prednisone; Prognosis; Survival Analysis; Thalidomide; Vincristine | 2016 |
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate; Thalidomide | 2016 |
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Remission Induction; Thalidomide; Treatment Outcome | 2016 |
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Lenalidomide; Male; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thalidomide | 2017 |
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2017 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Tumor Burden | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2017 |
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Placebos; Prednisone; Rituximab; Survival Rate; Thalidomide; Vincristine | 2017 |
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Lineage; Cyclophosphamide; Doxorubicin; Gene Expression Profiling; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2018 |
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2018 |
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Tumor Burden; Vincristine | 2018 |
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Translocation, Genetic; Treatment Outcome; Vincristine | 2019 |
Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Topics: Administration, Oral; Aged; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Hematinics; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prednisone; Treatment Outcome | 2019 |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Frail Elderly; Frailty; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Thalidomide | 2020 |
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Progression-Free Survival; Treatment Outcome | 2020 |
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Quality of Life; Rituximab; Vincristine | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prognosis; Rituximab; Tumor Burden; Vincristine | 2020 |
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Vincristine; Young Adult | 2021 |
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Disease Progression; Drug Administration Schedule; Eligibility Determination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Thalidomide; Time Factors; United States | 2020 |
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prospective Studies; Rituximab; Treatment Outcome; Vincristine | 2020 |
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Vincristine; Young Adult | 2021 |
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Vincristine; Young Adult | 2021 |
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prednisone; Treatment Outcome; Vincristine | 2021 |
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Progression-Free Survival; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2021 |
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Vincristine | 2023 |
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Vincristine | 2023 |
58 other study(ies) available for prednisone and lenalidomide
| Article | Year |
|---|---|
Current treatment of myelofibrosis.
Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Management; Drug Therapy, Combination; Esophageal and Gastric Varices; Farnesyltranstransferase; Gastrointestinal Hemorrhage; Hematopoietic Cell Growth Factors; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quinazolines; Spleen; Splenectomy; Thalidomide; Transplantation, Homologous | 2005 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors | 2006 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Incidence; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prednisone; Risk Factors; Survival Rate; Thalidomide; Venous Thrombosis | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2008 |
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglobulin Light Chains; Ischemia; Lenalidomide; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Thalidomide | 2009 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane | 2011 |
[Study to castrate-resistant prostate cancer: AUO study AP 60/10].
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Lenalidomide; Male; Prednisone; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Failure | 2011 |
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Models, Animal; Erythrocyte Indices; Erythropoiesis; Gene Expression Regulation, Developmental; Hemoglobins; Heterozygote; Lenalidomide; Lymphopenia; Mice; Mice, Inbred C57BL; Prednisone; Ribosomal Protein S6; Ribosomal Proteins; Ribosomes; RNA-Binding Proteins; Thalidomide; Thrombocytosis | 2012 |
Drug interaction between lenalidomide and itraconazole.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Female; Humans; Intestinal Absorption; Itraconazole; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide | 2012 |
Lenalidomide in myeloma--a high-maintenance friend.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2012 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2013 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drugs, Investigational; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Organoplatinum Compounds; Polyethylene Glycols; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vinblastine; Vinorelbine | 2013 |
Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.
Topics: Antineoplastic Agents, Hormonal; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Remission Induction; Thalidomide | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
[Crystalline keratopathy due to kappa chains in a monoclonal gammopathy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Corneal Opacity; Crystallization; Cyclophosphamide; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Kidney Failure, Chronic; Lenalidomide; Male; Melphalan; Middle Aged; Paraproteinemias; Paraproteins; Phacoemulsification; Postoperative Complications; Prednisone; Slit Lamp; Thalidomide | 2013 |
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymph Nodes; Lymphoma, T-Cell; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Recurrence; Retreatment; Thalidomide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
[Suspected itchy rash secondary to lenalidomide].
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Drug Eruptions; Exanthema; Female; Humans; Lenalidomide; Prednisone; Thalidomide | 2014 |
R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Thalidomide; Vincristine | 2014 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Clinical Trials, Phase II as Topic; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thalidomide | 2015 |
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years; Thalidomide; Treatment Outcome; United States | 2016 |
Continued role for ASCT in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine | 2016 |
Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.
Topics: Aged; Blood Transfusion; Comorbidity; Fatal Outcome; Female; Granuloma; Histiocytes; Humans; Lenalidomide; Multiple Organ Failure; Myelodysplastic Syndromes; Neutrophils; Paraneoplastic Syndromes; Prednisone; Thalidomide | 2017 |
Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
Topics: Adult; Aged; Child; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine | 2017 |
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; Hospitals, University; Humans; Lenalidomide; Male; Medication Adherence; Melphalan; Multiple Myeloma; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Prospective Studies; Thalidomide | 2018 |
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Topics: Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Czech Republic; Erythropoietin; Female; Genes, p53; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prednisone; Recurrence; Remission Induction; Risk Factors | 2018 |
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Fatigue; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Polyneuropathies; Prednisone; Thalidomide | 2018 |
Lenalidomide and R-CHOP in follicular lymphoma: where do we go from here?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lenalidomide; Lymphoma, Follicular; Prednisone; Rituximab; Thalidomide; Vincristine | 2018 |
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine | 2018 |
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Plasmapheresis; POEMS Syndrome; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2019 |
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Case-Control Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Registries; Safety; Stem Cell Transplantation | 2021 |
Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report.
Topics: Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Examination; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Skin Neoplasms; Transplantation, Autologous; Vincristine | 2020 |
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunotherapy; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Standard of Care; Treatment Outcome | 2021 |
Transient atelectasis due to hilar lymph node swelling affected by lenalidomide-induced tumor flare reaction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymph Nodes; Lymphoma, Follicular; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Prednisone; Pulmonary Atelectasis; Radiography, Thoracic; Rituximab; Vincristine | 2021 |
Extranodal blastoid/pleomorphic variant of mantle cell lymphoma involving the testis and skin.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Orchiectomy; Positron-Emission Tomography; Prednisone; Proto-Oncogene Proteins c-myc; Radiotherapy; Rituximab; Skin Neoplasms; Testicular Neoplasms; Vincristine | 2021 |
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2021 |
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CD28 Antigens; Cyclophosphamide; DNA Copy Number Variations; Doxorubicin; Etoposide; Female; Genes, p53; Hematopoietic Stem Cell Transplantation; Humans; INDEL Mutation; Kaplan-Meier Estimate; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mutation; Nitrosourea Compounds; Polymorphism, Single Nucleotide; Prednisolone; Prednisone; Prognosis; Receptors, CCR4; Vincristine; Vindesine | 2021 |
Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclin D1; Cyclophosphamide; Doxorubicin; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Lymphoma, Mantle-Cell; Male; Neoplasm Proteins; Positron Emission Tomography Computed Tomography; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; Remission Induction; Rituximab; Vincristine | 2021 |
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Frail Elderly; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Retrospective Studies; Rituximab | 2022 |
IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series.
Topics: Bortezomib; Cyclophosphamide; Dexamethasone; Humans; IgA Vasculitis; Immunoglobulin A; Lenalidomide; Melphalan; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Retrospective Studies; Rituximab | 2022 |
Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Neutropenia; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Tumor Microenvironment; Vincristine | 2023 |
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2023 |
Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Registries; Retrospective Studies; Treatment Outcome | 2023 |
A new frontier for R-CHOP: is two better than one?
Topics: Cyclophosphamide; Lenalidomide; Prednisone; Rituximab; Vincristine | 2023 |